Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833040 · ClinicalTrials.gov registry record · Phase 2
A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain
A Phase 2 study, sponsored by Talphera.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00833040 is a Phase 2 study that has completed, run by Talphera. The registered enrollment target is 34 participants.
The verdict
NCT00833040, a Phase 2 study, has completed, sponsored by Talphera.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this research study was to evaluate ARX-F02 (Sufentanil NanoTab) versus placebo ("sugar" pill or inactive substance) in the management of breakthrough pain in cancer patients.
Interventions
- DRUG Sublingual sufentanil NanoTabs™ and placebo NanoTabs™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833040
The ClinicalTrials.gov registry entry for NCT00833040 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Talphera, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sublingual sufentanil NanoTabs™ and placebo NanoTabs™ is the first listed.
NCT00833040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00833040 about?
NCT00833040 is a clinical study titled "A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain". The purpose of this research study was to evaluate ARX-F02 (Sufentanil NanoTab) versus placebo ("sugar" pill or inactive substance) in the management of breakthrough pain in cancer patients.
What is the current status of trial NCT00833040?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2009-04. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00833040?
The interventions under investigation include: Sublingual sufentanil NanoTabs™ and placebo NanoTabs™ (DRUG).
Who is sponsoring clinical trial NCT00833040?
This trial is sponsored by Talphera, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.